Bayer throws $22 million more at Broad collaboration

2 July 2018

German pharma major Bayer (BAYN: DE) has announced a new chapter in its partnership with US research center The Broad Institute of MIT and Harvard.

They have given the latest addition to their collaboration the name Precision Cardiology Laboratory (PCL). It will pursue scientific insights aimed at developing new therapies for heart failure.

Research in the PCL will bring scientists from both organizations into an integrated work space at the Broad Institute, combining the research center’s methods for basic scientific discovery and the clinical expertise of its practicing physicians with Bayer’s long history of drug development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK